SGLT2 inhibitorrelated adverse effects, including genital mycotic infections, volume depletion, and rarely ketoacidosis, remain clinically relevant and should be considered when these agents are prescribed as part of combination therapy and importantly, the intrinsic risk of hypoglycemia with combined GLP-1 receptor agonist and SGLT2 inhibitor therapy is low because neither class directly stimulates insulin secretion in a glucose-independent manner and when hypoglycemia occurs, it is more commonly related to concomitant insulin or sulfonylurea use rather than the combination itself [41, 42, 44]
Understanding Peptide Weight Loss Therapy Peptides are naturally occurring compounds made up of short chains of amino acids the building blocks of proteins
Improved Glycemic Control in T2D Tirzepatide's FDA approval for type 2 diabetes was granted following completion of five phase-3 trials in the SURPASS global clinical development program
Romeo, S
Mit Einverstndnis von Frau Schneider fge ich Auszge aus ihrem sehr interessanten Brief bei, bevor ich darauf eingehe und die komplizierten Mechanismen der Wechselwirkungen erlutere
Diabetes Care 43 , S66S76 (2020)
